CR8465A - Hormonas de administracion transdermica que no necesitan potenciadores de penetracion - Google Patents

Hormonas de administracion transdermica que no necesitan potenciadores de penetracion

Info

Publication number
CR8465A
CR8465A CR8465A CR8465A CR8465A CR 8465 A CR8465 A CR 8465A CR 8465 A CR8465 A CR 8465A CR 8465 A CR8465 A CR 8465A CR 8465 A CR8465 A CR 8465A
Authority
CR
Costa Rica
Prior art keywords
patch
hormones
potentiators
transdermal administration
need
Prior art date
Application number
CR8465A
Other languages
English (en)
Inventor
Bracht Stefan
Dittgen Michael
Huber Petra
Langguth Thomas
Schenk Dirk
Original Assignee
Bayer Shering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34924031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8465(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Shering Pharma Ag filed Critical Bayer Shering Pharma Ag
Publication of CR8465A publication Critical patent/CR8465A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere a un parche que comprende una capa de droga con un bajo contenido de hormonas, como por ejemplo gestodeno, y opcionalmente un estrogeno (por ejemplo etinilestradiol). Al aplicar el parche a una mujer, se consiguen niveles de plasma de al menos 1,0ng/ml de gestodeno en condiciones de estado estacionario sin necesidad de incorporar potenciadores de penetracion ni mejoradores de permeacion en la capa que contiene droga. Tambien son satisfactorios los niveles en plasma de las hormonas que se consiguen durante todo un periodo de al menos una semana, haciendo que el parche se pueda aplicar para utilizarlo en anticoncepcion femenina con el concepto de aplicar el parche una vez a la semana.
CR8465A 2003-12-12 2006-06-20 Hormonas de administracion transdermica que no necesitan potenciadores de penetracion CR8465A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52871803P 2003-12-12 2003-12-12
EP03078881 2003-12-12

Publications (1)

Publication Number Publication Date
CR8465A true CR8465A (es) 2007-06-06

Family

ID=34924031

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8465A CR8465A (es) 2003-12-12 2006-06-20 Hormonas de administracion transdermica que no necesitan potenciadores de penetracion

Country Status (23)

Country Link
EP (2) EP2138169B1 (es)
CN (1) CN101843603B (es)
AR (1) AR046762A1 (es)
AT (1) ATE457168T1 (es)
CR (1) CR8465A (es)
CY (2) CY1110637T1 (es)
DE (1) DE602004025444D1 (es)
DK (2) DK2138169T3 (es)
ES (2) ES2340925T3 (es)
GT (1) GT200400262A (es)
HN (1) HN2004000526A (es)
HR (2) HRP20100254T1 (es)
JO (1) JO2606B1 (es)
ME (1) ME01069B (es)
MY (2) MY144053A (es)
PE (1) PE20051035A1 (es)
PL (2) PL1541137T3 (es)
PT (2) PT1541137E (es)
RS (2) RS51260B (es)
SI (2) SI1541137T1 (es)
SV (1) SV2006001970A (es)
TW (1) TWI257299B (es)
UA (1) UA89766C2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1594483T1 (sl) 2003-02-21 2006-12-31 Schering Ag UV-stabilni transdermalni terapevtski obliz
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
CA2740002C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
EP2343964A4 (en) 2008-10-08 2012-11-07 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
CA2740005C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
WO2010111488A1 (en) * 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery
ES2617334T3 (es) 2010-09-06 2017-06-16 Bayer Intellectual Property Gmbh Parches transdérmicos de dosificación baja con liberación elevada de fármaco
DE102010040299A1 (de) * 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
AU2015203180B2 (en) * 2010-09-06 2016-06-30 Bayer Intellectual Property Gmbh Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
HK1204287A1 (en) * 2012-01-27 2015-11-13 敏捷治疗公司 Transdermal hormone delivery

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4081537A (en) 1975-10-10 1978-03-28 Schering Aktiengesellschaft Δ15 -Steroids and pharmaceutical compositions thereof
EP0394429B1 (de) * 1988-10-27 1996-01-10 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend gestoden
US5512292A (en) 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
MX9101787A (es) 1990-10-29 1992-06-05 Alza Corp Formulaciones,metodos y dispositivos anticonceptivos transdermicos
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
JP4841781B2 (ja) 1999-11-24 2011-12-21 アジル・セラピューティクス・インコーポレイテッド 改良された経皮的避妊薬送達系および方法
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
TWI287455B (en) * 2000-12-05 2007-10-01 Noven Pharma Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use

Also Published As

Publication number Publication date
MY152750A (en) 2014-11-28
JO2606B1 (en) 2011-11-01
SV2006001970A (es) 2006-02-16
HK1132682A1 (en) 2010-03-05
ES2340925T3 (es) 2010-06-11
EP1541137A3 (en) 2005-11-16
SI2138169T1 (sl) 2014-03-31
GT200400262A (es) 2005-10-31
PT2138169E (pt) 2014-02-17
CN101843603A (zh) 2010-09-29
RS53182B (sr) 2014-06-30
HRP20100254T1 (hr) 2010-06-30
ME01069B (me) 2012-10-20
PL2138169T3 (pl) 2014-04-30
CY1115064T1 (el) 2016-12-14
CY1110637T1 (el) 2015-04-29
EP2138169A2 (en) 2009-12-30
UA89766C2 (en) 2010-03-10
DE602004025444D1 (de) 2010-03-25
DK2138169T3 (da) 2013-11-18
HN2004000526A (es) 2010-02-01
RS51260B (sr) 2010-12-31
TW200528073A (en) 2005-09-01
EP2138169B1 (en) 2013-11-06
TWI257299B (en) 2006-07-01
PT1541137E (pt) 2010-05-17
CN101843603B (zh) 2012-06-27
HRP20140077T1 (hr) 2014-02-28
DK1541137T3 (da) 2010-04-26
ES2445690T3 (es) 2014-03-04
AR046762A1 (es) 2005-12-21
MY144053A (en) 2011-08-15
SI1541137T1 (sl) 2010-06-30
PL1541137T3 (pl) 2010-07-30
EP2138169A3 (en) 2011-04-06
ATE457168T1 (de) 2010-02-15
EP1541137A2 (en) 2005-06-15
EP1541137B1 (en) 2010-02-10
PE20051035A1 (es) 2006-02-08
HK1074801A1 (en) 2005-11-25

Similar Documents

Publication Publication Date Title
CU20100143A7 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
CY1115064T1 (el) Διαδερμικο συστημα παραδοσης ορμονων χωρις ενισχυτες διεισδυσης
EE9900288A (et) Peroraalselt manustatava farmatseutilise kompositsiooni kasutamine meeste erektiilse talitlushäire raviks ettenähtud ravimi valmistamiseks
DK0836506T4 (da) Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
NO20024586L (no) FremgangsmÕte og preparat for prevensjon av hormoninduserte ugunstige virkninger
MXPA04005211A (es) Sistemas terapeuticos transdermicos que contienen hormona esteroides y monocaprilato de propilenglicol.
CR7610A (es) Uso de derivados de thio-oxindol en el tratamiento de condiciones realcionadas con la hormona
DE602005026290D1 (de) Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
CR10732A (es) Uso de valerato de estradiol o 17 b- estradiol en combinacion con dienogest en una terapia oral para mantener y / o incrementar la libido femenina
PE20060467A1 (es) Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos
AR021459A1 (es) PARCHE QUE CONTIENE ESTRADIOL PARA LA APLICACIoN PERCUTÁNEA DE HORMONAS.
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
CR10289A (es) "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional)
UY28668A1 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
AR049197A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
CU23649B7 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
CR8059A (es) Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas
PE20070119A1 (es) Nuevos regimenes para dispositivos de suministro controlado de farmacos para la anticoncepcion
DE69918124D1 (de) Formulierungen zur transdermalen verabreichung von fenoldopam
Lewis Treatment of Erectile Dysfunction: Today and Tomorrow
DOP2005000263A (es) Emplasto transdermico con ligandos especificos de progesterona a (prasl) como principio activo.